Brings over 30 years of experience working with emerging growth life sciences companies
New Haven, Conn., October 10, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors, effective immediately. Ms. VanLent will serve as Chair of the Audit Committee.
Ms. VanLent joins Trevi’s Board with over 30 years of experience working with emerging growth life sciences companies. She founded and serves as President of AMV Advisors, an advisory firm that provides strategic and management consulting services to emerging growth companies in the life sciences industry. Ms. VanLent has held senior executive and financial leadership roles with Barrier Therapeutics, Inc., Sarnoff Corporation (a division of SRI International), Trophix Pharmaceuticals, Inc. and The Liposome Company, Inc. She is currently a member of the board of directors and audit chair of both Vaxart, Inc. and Advanced Genetic Technologies, Inc. and has held prior board seats for Ocera, Novelion, Onconova, Integra Life Sciences, Penwest Pharmaceuticals, and several private companies. Ms. VanLent received a B.A. in Physics from Mount Holyoke College.
“Anne brings extensive strategic and financial experience in management and board governance of life sciences companies. Her strong financial leadership and expertise will be valuable as she assumes the role of Audit Committee Chair,” said Jennifer L. Good, President and Chief Executive Officer.
“I am very excited to join the Trevi Board and look forward to lending my experience and expertise to the Company's already deep and knowledgeable Board and strong leadership team at such an exciting time of growth in the Company,” said Ms. VanLent.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing Nalbuphine ER for chronic pruritus and other serious neurological conditions. Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. The Company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. Prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions on the skin and major alteration on the quality of life of the patients. There are no approved therapies in the U.S. or EU for this condition. Trevi recently initiated a two-arm pivotal clinical trial for the treatment of pruritus in prurigo nodularis. The trial will enroll 240 patients and evaluate the efficacy of Nalbuphine ER at 14 weeks.
About Nalbuphine ER
Nalbuphine ER is an oral extended release formulation of nalbuphine that is both a mixed mu receptor antagonist and a kappa receptor agonist. Each of these mechanisms of action has been shown in research to be effective in abolishing itch, and the neurobiology of these mechanisms of action indicates that these mechanisms have a dynamic and synergistic relationship. Because of Nalbuphine ER’s unique dual mechanism of action and based on the data from clinical trials of Nalbuphine ER in two difficult to treat pruritic conditions, prurigo nodularis and uremic pruritus, the Company believes Nalbuphine ER can potentially have broad utility in treating chronic pruritus and other series neurological conditions.
Founded in 2011, Trevi Therapeutics is headquartered in New Haven, Conn. For additional information, visit www.trevitherapeutics.com.